Standard Long-Course Chemoradiotherapy Regimen for Rectal Cancer
The standard long-course chemoradiotherapy (LCCRT) regimen consists of 50.4 Gy delivered in 28 fractions (1.8 Gy per fraction) over 5-6 weeks with concurrent fluoropyrimidine-based chemotherapy, typically capecitabine or continuous infusion 5-fluorouracil (5-FU). 1, 2
Radiation Dosing and Schedule
The radiation component delivers:
- Total dose: 50.4 Gy (some protocols use 45-50 Gy)
- Fractionation: 1.8 Gy per fraction
- Schedule: 28 fractions over 5-6 weeks (5 days per week)
Concurrent Chemotherapy Options
Capecitabine-based (most common):
5-FU-based (alternative):
- Continuous intravenous infusion 5-FU 1000 mg/m² per day during weeks 1 and 5 of radiation 2
- Some protocols use 225 mg/m² daily throughout radiation
Timing and Surgical Interval
- Surgery (total mesorectal excision) is performed 6-8 weeks after completion of chemoradiotherapy 2, 3
- This interval allows for maximal tumor downstaging and response assessment
Contemporary Context: Total Neoadjuvant Therapy
Important caveat: While LCCRT remains a standard option, the 2024 ASCO guidelines now recommend total neoadjuvant therapy (TNT) as the preferred approach for locally advanced rectal cancer 1. TNT incorporates systemic chemotherapy (typically FOLFOX or CAPOX) either before (induction) or after (consolidation) the LCCRT, rather than reserving chemotherapy for the adjuvant setting.
When LCCRT is used within TNT:
- Consolidation approach: LCCRT followed by 4 cycles of CAPOX or 6 cycles of FOLFOX before surgery 5, 3
- Induction approach: 4-6 cycles of chemotherapy first, then LCCRT before surgery 5
The consolidation approach (chemoRT first) may yield higher pathologic complete response rates (25% vs 17%) compared to induction chemotherapy first 5.
Evidence Supporting LCCRT
The landmark 2004 German trial established preoperative LCCRT as superior to postoperative treatment, demonstrating:
- Better local control (6% vs 13% local recurrence at 5 years, P=0.006)
- Reduced toxicity (27% vs 40% grade 3-4 acute toxicity, P=0.001)
- No difference in overall survival 2
LCCRT vs Short-Course Radiotherapy
LCCRT is preferred over short-course radiotherapy (SCRT) in the TNT setting per ASCO 2024 guidelines 1. While SCRT (25 Gy in 5 fractions) followed by chemotherapy shows comparable pathologic complete response rates, the RAPIDO trial's 5-year data revealed higher local recurrence with SCRT (10% vs 6%, P=0.027) 5. This is a critical consideration for morbidity and quality of life.
Key Clinical Pitfalls
- Do not use SCRT alone without chemotherapy for locally advanced disease—this is inadequate systemic therapy
- Ensure adequate radiation field coverage including mesorectal fascia and regional lymph nodes
- Monitor for acute toxicities during treatment: diarrhea (most common), skin reactions, and hematologic toxicity
- Consider patient factors: LCCRT requires 5-6 weeks of daily treatment vs 1 week for SCRT, affecting treatment burden and compliance